{"id":918276,"date":"2025-12-10T08:05:24","date_gmt":"2025-12-10T13:05:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/"},"modified":"2025-12-10T08:05:24","modified_gmt":"2025-12-10T13:05:24","slug":"dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/","title":{"rendered":"DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <em>Developed and evaluated specifically for women, DARE to PLAY\u2122 Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal<\/em><br \/>\n        <em>topical cream shown in clinical studies to increase genital blood flow in 10\u201315 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY\u2122 is expected to mark a breakthrough in women\u2019s sexual health and represents important progress toward closing one of medicine\u2019s most persistent gender gaps.<\/em>\n      <\/p>\n<p>SAN DIEGO, Dec.  10, 2025  (GLOBE NEWSWIRE) &#8212; <strong>Dare\u0301 Bioscience, Inc. (NASDAQ: DARE),<\/strong> a purpose-driven health biotech company solely focused on closing the gap in women\u2019s health between promising science and real-world solutions, today announced that providers in select states can now begin prescribing DARE to PLAY\u2122 Sildenafil Cream, a proprietary topical arousal cream designed specifically for women to enhance genital blood flow and arousal response.<\/p>\n<p>DARE to PLAY\u2122 represents the first and only evidence-backed sildenafil cream formulation for women. Its commercial availability through a 503B outsourcing facility will mark the first time a topical sildenafil formulation manufactured in accordance with cGMP requirements and supported by clinical data will be accessible to women.<\/p>\n<p>DARE to PLAY\u2122 uses sildenafil, the same active ingredient found in Viagra\u00ae, to improve genital blood flow. Applied topically, it\u2019s designed for use as needed, to enhance the body\u2019s natural arousal response without systemic effects, providing women with a new, evidence-based tool to take charge of their sexual health.<\/p>\n<p>\u201cWhen Viagra was approved in 1998, it revolutionized sexual medicine for men. But for women, comparable progress on enhancing the natural arousal sensations has stalled for nearly three decades,\u201d said Sabrina Martucci Johnson, President and CEO of Dar\u00e9 Bioscience. \u201cWe believe DARE to PLAY\u2122 represents a long overdue correction, giving women an option to reconnect with their own bodies, their pleasure, and their confidence, using science that finally recognizes their needs.\u201d<\/p>\n<p>Existing products promoted for arousal lean heavily on marketing language, consumer reviews, and lifestyle branding without real evidence. DARE to PLAY\u2122 is the first and only topical formulation of sildenafil developed specifically for women and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lrXrTh_CoLB_86N-DIyzT2qLEEjCt0a87E-5v7ged4XhFU4ahIvcHE9zt-mRkZ-0pFFL67M8I6CZFlkltqaKbQ==\" rel=\"nofollow\" target=\"_blank\">backed by<\/a>:<\/p>\n<ul type=\"disc\">\n<li>Toxicology studies covering oral, anal, vaginal, and reproductive health;<\/li>\n<li>Multiple clinical trials in women, including a randomized placebo-controlled study with 200 women and their sexual partners; and<\/li>\n<li>Published, peer-reviewed research in medical journals such as The Green Journal, the official publication of the American College of Obstetrics and Gynecology (ACOG) and the Journal of Sexual Medicine, the official publication of the International Society for the Study of Women\u2019s Sexual Health (ISSWSH).<\/li>\n<\/ul>\n<p>\u201cAs more women speak openly about their sexual health, the need for research-backed solutions has never been greater,\u201d said Dr. Irwin Goldstein, Director of San Diego Sexual Medicine and a founder of ISSWSH. \u201cDar\u00e9\u2019s commitment to both clinical integrity and timely access ensures women who need it don\u2019t have to wait to benefit from this innovation.\u201d<\/p>\n<p>While continuing activities necessary to seek U.S. Food and Drug Administration (FDA) approval of its proprietary sildenafil cream formulation in the future, Dar\u00e9 Bioscience is making DARE to PLAY\u2122 available as a Section 503B compounded product, manufactured in an outsourcing facility subject to FDA inspection and under current Good Manufacturing Practice (cGMP) regulations to ensure quality, strength and consistency. Compounded drug products are not FDA approved. The FDA does not evaluate compounded drug products for safety, effectiveness, or quality.<\/p>\n<p>DARE to PLAY\u2122 can now be prescribed for pre-order by licensed healthcare providers for prescription fulfillment in these states: CT, FL, IN, MO, NH, NJ, OR, PA, RI, and UT, and will ship within 45 days of order placement during the pre-order phase. DARE to PLAY\u2122 prescriptions are being accepted through the DARE Health Hub, managed by Medvantx. DARE to PLAY\u2122 will be available in other states throughout December and early 2026. Visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h0HseZIHVw87i8lmGJzczdsLr-Ezh3NuuhS_OqQTvDyEfYubvi6Xxa3ASdfKq1_uG-mRWCx6dV7g7DB3c2caf-O2Pb4xHTq2mrQMZUD3dw4=\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/daretoplaybio.com\/<\/u><\/a> for more information on DARE to PLAY\u2122, including how to access a prescription and to sign up for an alert on when it is available in your state.<\/p>\n<p>\n        <strong>Market Opportunity <\/strong>\n      <\/p>\n<p>An estimated 20 million women in the United States experience challenges related to genital arousal, yet there are no FDA-approved therapeutics to address this need. The availability of DARE to PLAY\u2122 through a cGMP 503B facility provides this large, underserved community of women access to a product uniquely supported by clinical evidence and scientific rigor.<\/p>\n<p>\n        <strong>Section 503B<\/strong>\n      <\/p>\n<p>References to Section 503B, 503B, 503B compounding, 503B compounded product, and similar terms refer to Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) and the production and supply of compounded drugs by Section 503B-registered outsourcing facilities without patient-specific prescriptions in accordance with Section 503B.<\/p>\n<p>\n        <strong>About Dar\u00e9 Bioscience<\/strong>\n      <\/p>\n<p>Dar\u00e9 Bioscience is a purpose-driven health biotech company solely focused on closing the gap in women&#8217;s health between promising science and real-world solutions. Every innovation Dar\u00e9 advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, Dar\u00e9 is working to close critical gaps in care using science that serves her needs.<\/p>\n<p>For decades, women have been told to \u201cwait it out\u201d or \u201clive with it,\u201d while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to real, evidence-based solutions continues to lag. Dar\u00e9 was founded to change that. As a female-led health biotech company, Dar\u00e9 is accelerating the development of credible, science-based solutions that meet the high standards of clinical rigor \u2013 randomized, controlled trials; validated endpoints; peer-reviewed publications; and current Good Manufacturing Practice (cGMP) requirements.<\/p>\n<p>To learn more about Dar\u00e9\u2019s mission to deliver differentiated therapies for women and its innovation pipeline, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VNSUP01e67oUYurbFxV4gjLSJ7e6BpwA6uarsQWfAIpGSvktIXa36slkaTU7VLXs1l2J3gMigqnGD5eG3f6jv6XCp8vEBpcpM3lQZ7xLozk=\" rel=\"nofollow\" target=\"_blank\">www.darebioscience.com<\/a>.<\/p>\n<p>Dar\u00e9 Bioscience leadership has been named on the Medicine Maker\u2019s Power List and Endpoints News\u2019 Women in Biopharma and Dar\u00e9&#8217;s CEO has been honored as one of Fierce Pharma\u2019s Most Influential People in Biopharma for Dar\u00e9\u2019s contributions to innovation and advocacy in the women\u2019s health space.<\/p>\n<p>Dar\u00e9 may announce material information about its finances, products and product candidates, clinical trials and other matters using the Investors section of its website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aOfhdrR8nEaNj6vRG7CJGHDsr-SU1odQoEHb9n6UyhCQimURmOosp5YBuy8TnPtKJtFFFipbodVeeEfFcrDJsgoatLFomUBDya2tqWkV2bDEz3_RHY84EuJRgDoRYxz3\" rel=\"nofollow\" target=\"_blank\">http:\/\/ir.darebioscience.com<\/a>),\u00a0SEC\u00a0filings, press releases, public conference calls and webcasts. Dar\u00e9 will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, products and product candidates, clinical trials and other matters. The information Dar\u00e9 posts on its investor relations website or through social media channels may be deemed to be material information. Dar\u00e9 encourages investors, the media, and others interested in the company to review the information Dar\u00e9 posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Dar\u00e9\u2019s website.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Dar\u00e9 cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cexplore\u201d \u201cobjective,\u201d \u201con track,\u201d or the negative version of these words and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to plans and timing for commercial availability of DARE to PLAY\u2122 Sildenafil Cream in states in the\u00a0U.S., production of the compounded drug product in accordance with cGMP requirements, the ability of the product to enhance genital arousal response in women without systemic effects, the market opportunity for the product, its market position, its impact in women\u2019s sexual health, and its ability to gain market acceptance, and Dar\u00e9\u2019s plans to seek FDA approval of its sildenafil cream formulation, pending additional development activities. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dar\u00e9\u2019s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Dar\u00e9\u2019s reliance on a Section 503B-registered outsourcing facility, a licensed dispensing pharmacy with an online platform, and other third parties to bring DARE to PLAY\u2122 Sildenafil Cream to market and facilitate access to the product and the risk that those third parties do not perform as expected; difficulties in establishing and sustaining relationships with third-party collaborators; the risk that FDA could stop permitting Section 503B-registered outsourcing facilities to manufacture and fulfill orders for compounded sildenafil products or change the conditions under which sildenafil may be used in compounding or compounded sildenafil products may be distributed; the ability of Dar\u00e9\u2019s outsourcing facility partner to maintain its registration with the FDA under Section 503B of the Federal Food, Drug, and Cosmetic Act; the timing of establishing, and ability to maintain, state-required licensure or registration to enable fulfillment of prescriptions for DARE to PLAY\u2122 Sildenafil Cream; Dar\u00e9\u2019s inexperience, as a company, in and lack of infrastructure for commercializing products; the degree of market demand and acceptance for DARE to PLAY\u2122 Sildenafil Cream; competitive product launches; greater than expected costs to bring compounded drug products to market and marketing costs; shifts in consumer spending or behavior; Dar\u00e9\u2019s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; Dar\u00e9\u2019s dependence on grants and other financial awards from governmental entities and a private foundation; limitations on Dar\u00e9\u2019s ability to raise additional capital through sales of its common stock or other equity securities due to restrictions under\u00a0SEC\u00a0and Nasdaq rules and regulations or contractual limitation; Dar\u00e9\u2019s ability to retain its licensed rights to develop and commercialize a product or product candidate; Dar\u00e9\u2019s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Dar\u00e9\u2019s ability to adequately protect or enforce its, or its licensor\u2019s, intellectual property rights; disputes or other developments concerning Dar\u00e9\u2019s intellectual property rights; product liability claims; governmental investigations or actions relating to Dar\u00e9\u2019s products or product candidates or the business activities of Dar\u00e9, its commercial collaborators or other third parties on which Dar\u00e9 relies; changes in healthcare, pharmaceutical, consumer protection or privacy laws and regulatory policies; increased scrutiny from regulators; Dar\u00e9\u2019s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, completing or conducting clinical trials of a product candidate and the inherent uncertainty of outcomes of clinical trials; the risks that positive findings in early clinical and\/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and\/or nonclinical studies of that candidate and that interim data or results from a particular clinical study do not necessarily predict the final results for that study; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Dar\u00e9\u2019s interpretation of or conclusions regarding data from clinical studies of its product candidates; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in\u00a0U.S.\u00a0government policies and operations on Dar\u00e9\u2019s ability to raise additional capital or on Dar\u00e9\u2019s operations, financial results and condition, and ability to achieve current plans and objectives; Dar\u00e9\u2019s ability to maintain compliance with Nasdaq\u2019s continued listing requirements and continue to have its common stock listed on The Nasdaq Capital Market; and cybersecurity incidents or similar events that compromise Dar\u00e9\u2019s technology systems and\/or significantly disrupt Dar\u00e9\u2019s business or those of third parties on which Dar\u00e9 relies. Dar\u00e9\u2019s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Dar\u00e9\u2019s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission, including Dar\u00e9\u2019s recent filings on Form 8-K, Form 10-K and Form 10-Q. You\u00a0are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Dar\u00e9 undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Dar\u00e9 Bioscience Investor Relations<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JtIvCUkBOwq3yvCGEl2SGY4srtOKSD_W2ZrLZ0--GcDVcF1y2bdceAij5W5zE_NNv_q777CmDWW2HLYhUtDlhwaSRrPd_G9xpDrh8AEahkFazzw7ojInj-3DOvaTdrL2zrAxdPFztF9gD_iQLeGa5B95QA9xcMxY11GIUxszhDaTNW_EXc8smMZ8_osXspYyVjH4er9MrnXurm55VJN0mCvhw8BFtyLEYjr0BIA8gZdIdeSv4A14KJIudeN2HPzT5FvmwtyHDpQgT4oOL8qjdf6FTMhGTv-ubMSi3qb49BVmzukHU_Q5MwevGqojeI4O\" rel=\"nofollow\" target=\"_blank\">innovations@darebioscience.com<\/a>\n      <\/p>\n<p>Source: Dar\u00e9\u00a0Bioscience, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTg3MiM3MzE0ODg4IzIwMDgzNjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjAyNTljM2ItODNmZS00OWY4LWEyN2MtMWYwYWM3MGUyZmU3LTEwMTk5MzctMjAyNS0xMi0xMC1lbg==\/tiny\/Dar-Bioscience-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Developed and evaluated specifically for women, DARE to PLAY\u2122 Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10\u201315 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY\u2122 is expected to mark a breakthrough in women\u2019s sexual health and represents important progress toward closing one of medicine\u2019s most persistent gender gaps. SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) &#8212; Dare\u0301 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women\u2019s health between promising science and real-world solutions, today announced that providers in select states can now begin prescribing DARE to PLAY\u2122 Sildenafil Cream, a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-918276","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Developed and evaluated specifically for women, DARE to PLAY\u2122 Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10\u201315 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY\u2122 is expected to mark a breakthrough in women\u2019s sexual health and represents important progress toward closing one of medicine\u2019s most persistent gender gaps. SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) &#8212; Dare\u0301 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women\u2019s health between promising science and real-world solutions, today announced that providers in select states can now begin prescribing DARE to PLAY\u2122 Sildenafil Cream, a &hellip; Continue reading &quot;DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-10T13:05:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTg3MiM3MzE0ODg4IzIwMDgzNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility\",\"datePublished\":\"2025-12-10T13:05:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/\"},\"wordCount\":2157,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5OTg3MiM3MzE0ODg4IzIwMDgzNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/\",\"name\":\"DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5OTg3MiM3MzE0ODg4IzIwMDgzNjQ=\",\"datePublished\":\"2025-12-10T13:05:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5OTg3MiM3MzE0ODg4IzIwMDgzNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5OTg3MiM3MzE0ODg4IzIwMDgzNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/","og_locale":"en_US","og_type":"article","og_title":"DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - Market Newsdesk","og_description":"Developed and evaluated specifically for women, DARE to PLAY\u2122 Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10\u201315 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY\u2122 is expected to mark a breakthrough in women\u2019s sexual health and represents important progress toward closing one of medicine\u2019s most persistent gender gaps. SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) &#8212; Dare\u0301 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women\u2019s health between promising science and real-world solutions, today announced that providers in select states can now begin prescribing DARE to PLAY\u2122 Sildenafil Cream, a &hellip; Continue reading \"DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-10T13:05:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTg3MiM3MzE0ODg4IzIwMDgzNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility","datePublished":"2025-12-10T13:05:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/"},"wordCount":2157,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTg3MiM3MzE0ODg4IzIwMDgzNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/","name":"DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTg3MiM3MzE0ODg4IzIwMDgzNjQ=","datePublished":"2025-12-10T13:05:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTg3MiM3MzE0ODg4IzIwMDgzNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTg3MiM3MzE0ODg4IzIwMDgzNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-to-play-sildenafil-cream-now-available-for-pre-order-by-prescription-first-evidence-based-topical-arousal-cream-for-women-begins-commercial-rollout-in-select-states-via-503b-outsourcing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DARE to PLAY\u2122 Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/918276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=918276"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/918276\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=918276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=918276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=918276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}